Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
89Bio Inc
(NQ:
ETNB
)
8.180
-0.150 (-1.80%)
Streaming Delayed Price
Updated: 1:17 PM EDT, Sep 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 89Bio Inc
< Previous
1
2
3
Next >
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 08, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
October 17, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/19
April 19, 2023
Via
Investor Brand Network
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/10
April 10, 2023
Via
Investor Brand Network
89Bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 3/31
March 31, 2023
Via
Investor Brand Network
89Bio Inc. (NASDAQ: ETNB) Records 52-Week High Friday Morning
March 24, 2023
Via
Investor Brand Network
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
September 21, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the 2023 Cantor Global Healthcare Conference
September 20, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023
From
89bio, Inc.
Via
GlobeNewswire
89Bio Inc. (NASDAQ: ETNB) Near the Top of Equities by Percentage Gain on 3/22
March 22, 2023
Via
Investor Brand Network
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
June 24, 2023
From
89bio, Inc.
Via
GlobeNewswire
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
June 24, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023
June 07, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
May 23, 2023
First FGF21 analog to enter Phase 3 development
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
May 02, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
March 24, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
March 22, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)
March 22, 2023
89bio, Inc. (NASDAQ: ETNB) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of
Via
Spotlight Growth
Exposures
Product Safety
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
March 22, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 10, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
March 04, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
February 21, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the SVB Securities Global Biopharma Conference
February 08, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Provides Business Update and Outlook for 2023
January 04, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology
December 12, 2022
From
89bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.